Minerva logo
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
March 08, 2023 07:30 ET | Minerva Neurosciences, Inc
BURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
March 01, 2023 08:30 ET | Minerva Neurosciences, Inc
BURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
November 09, 2022 08:00 ET | Minerva Neurosciences, Inc
BURLINGTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
November 02, 2022 08:30 ET | Minerva Neurosciences, Inc
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market
September 09, 2022 16:05 ET | Minerva Neurosciences, Inc
BURLINGTON, Mass., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
August 22, 2022 08:00 ET | Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates
August 09, 2022 08:00 ET | Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates
May 04, 2022 08:30 ET | Minerva Neurosciences, Inc
WALTHAM, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva logo
Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
April 07, 2022 08:30 ET | Minerva Neurosciences, Inc
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company developing therapies to treat central nervous system (CNS)...
Minerva logo
Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates
March 01, 2022 07:30 ET | Minerva Neurosciences, Inc
WALTHAM, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV) a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...